Preclinical development and toxicology represent some of the most technically demanding and talent-scarce functions in the pharmaceutical industry. At senior level — Head of Toxicology, VP Preclinical, ToxPathologist, Head of DMPK — the combination of deep scientific specialism, regulatory understanding and leadership capability makes these among the hardest appointments a BioPharma company can make. In Europe, where the talent pool is genuinely limited, the challenge is even more acute.
Why niche preclinical functions are so hard to hire
The scarcity of senior preclinical talent in Europe stems from several compounding factors. These are genuinely specialist scientific disciplines that take years to develop — a strong ToxPathologist or DMPK leader with ten or more years of relevant experience and the ability to lead a team and engage with regulatory authorities is a rare profile in any geography.
Add the geographic concentration of European pharma — Switzerland, Germany, Denmark and the UK accounting for a disproportionate share of the activity — and the pool of candidates who are both appropriately qualified and willing to consider a move at any given moment becomes very small indeed.
In niche preclinical functions, the difference between a good search and a great one is almost entirely down to network depth. The right candidates are known relationships, not search results.
What successful searches in this space look like
The most successful preclinical and toxicology executive searches share a common characteristic — they are conducted by people who genuinely understand the science. A search partner who can't distinguish between a Toxicologist and a ToxPathologist, or who doesn't understand what PK/PD modelling actually involves, will struggle to identify the right candidates, assess them meaningfully or present an opportunity compellingly.
Retained searches in this space also tend to require more time and more patience than searches in broader functions. The right candidate may not be actively looking. They may be deeply embedded in a long-term programme. The conversation that eventually leads to a move may need to be built over months before the timing is right.
What companies should prioritise in their approach
Companies hiring at senior level in preclinical and toxicology functions in Europe should prioritise search partners with genuine scientific literacy and proven networks in these disciplines. They should also be realistic about timeline — expecting to move quickly in a thin talent market leads to compromises. The right approach is to start the search before urgency forces the decision, and to invest in the relationship-building that makes the eventual conversation possible.